Abstract: This document describes systems and techniques directed at autogenerated language model notifications. In aspects, a device management system associated with a network of network-connected devices includes a prompt manager. The prompt manager obtains metadata associated with the network and integrates at least portions of data from the metadata into one or more templated prompts to create an instantiated prompt. The instantiated prompt can be transmitted to a language model to generate a language model output. The prompt manager may then provide, based on the language model output, a notification to a user associated with at least one network-connected device. Through such a technique, the prompt manager can improve user experience and facilitate user proactiveness managing their network of network-connected devices.

Abstract: Systems, devices, and methods are provided for fingerprinting requests, such as transaction records. A transaction record or other suitable request may be parsed to identify a parameter values for a set of fields relevant to fingerprinting. A transaction record representation may be generated based on transaction input data, transaction output data, intermediate data, or combinations thereof. A fingerprint may be generated from the transaction record implementation. Fingerprints may be used to identify various test cases that can be used for regression testing.

Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the status of one or more mTOR-activating aberration at one or more genes selected from the group consisting of TSC1, TSC2, RPS6, PTEN, TP53, RB1, ATRX, and FAT1.

Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.

Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the status of one or more mTOR-activating aberration at one or more genes selected from the group consisting of TSC1, TSC2, RPS6, PTEN, TP53, RB1, ATRX, and FAT1.